Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T

Medicare covers inpatient and outpatient care for skin cancer. People with Original Medicare parts A and B or Medicare Advantage plans can expect extensive coverage, but they will likely have out ...

The cost of cancer may be higher than previously estimated, according to a recent report from the American Cancer Society.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.On Jan. 17, CMS announced it will commence negotiations with pharmaceutical companies to lower prices for Medicare Part D coverage for a wide range of drugs to treat multiple forms of cancer,

Most health insurance providers and Medicare cover Gentle Cure. Medicare Part A covers radiation therapy when you are receiving inpatient treatment in the hospital. Part B covers radiation therapy for outpatients or for those receiving treatment at a freestanding clinic.

Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news release.

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

Guardant Health, Inc. (NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy.

Medicare spending on cancer drugs may not be associated with the drugs’ clinical benefits, such as overall survival or progression-free survival.

Given forthcoming changes to Medicare Part D plans under the Inflation Reduction Act, CMS should collect and publish plan-level metrics describing how beneficiaries’ use of medications is impacted by formulary composition.

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and manufacturers.